REGENERON PHARMACEUTICALS, INC. Net Income Loss

• REGENERON PHARMACEUTICALS, INC. showed an increase of +2.1% in Net Income Loss from 2024 to 2025.
• This data is from REGENERON PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 4, 2026.
• XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 18 years of available data (2008 to 2025), REGENERON PHARMACEUTICALS, INC.'s Net Income Loss has grown by 5,793.1%.
• Historical annual values: Fiscal year 2025: $4.50 billion | Fiscal year 2024: $4.41 billion | Fiscal year 2023: $3.95 billion | Fiscal year 2022: $4.34 billion | Fiscal year 2021: $8.08 billion | Fiscal year 2020: $3.51 billion | Fiscal year 2019: $2.12 billion | Fiscal year 2018: $2.44 billion | Fiscal year 2017: $1.20 billion | Fiscal year 2016: $895.50 million | Fiscal year 2015: $636.06 million | Fiscal year 2014: $338.13 million | Fiscal year 2013: $413.74 million | Fiscal year 2012: $750.27 million | Fiscal year 2011: -$221.76 million | Fiscal year 2010: -$104.47 million | Fiscal year 2009: -$67.83 million | Fiscal year 2008: -$79.13 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026